The drug being tested in this study is called EA1080. EA1080 is being tested to find a safe and well-tolerated dose in healthy Caucasian and Japanese male participants. The study consists of 2 parts as mentioned below:~Part A: This part of the study is fully adaptive and will be performed in three sub-parts as follows:~Single ascending dose (SAD)~Food Effect (FE) and optional bioavailability~Multiple ascending dose (MAD)~Part B: This part of study is comprised of four sub-parts to assess Formulation E and Formulation F as follows:~SAD~An additional FE period in SAD cohorts (SAD-FE)~Food Effect and bioavailability (FE/BA)~MAD
The primary purpose of the study is to evaluate the safety and tolerability of EA1080 following single and multiple ascending oral doses in healthy Caucasian and Japanese male participants.